What are the indications for acotinib?

Acalabrutinib is an oral drug that is a BTK inhibitor and is suitable for the treatment of certain types of leukemia and lymphoma. Its main indications include but are not limited to:

1.Chronic lymphocytic leukemia (CLL): Chronic lymphocytic leukemia is a common type of leukemia in adults. The number of patients' B lymphocytes is abnormally increased, leading to abnormal immune system function.

2.Small cell lymphoma (SLL): Small cell lymphoma is a rare type of lymphoma that mainly affects the lymphatic system and is characterized by the presence of abnormally small lymphocytes in lymph nodes, spleen, bone marrow, and peripheral blood.

3.Follicular lymphoma (FL): Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by enlarged lymph nodes, soft texture, smooth surface, and a follicular structure pathologically.

4.Diffuse largeB cell lymphoma (DLBCL): Diffuse largeBcell lymphoma is the most common type of non-Hodgkin lymphoma. Lymphocytes within white blood cells proliferate abnormally and are highly heterogeneous.

These diseases are clinically heterogeneous. As a targeted therapy, acotinib targets specific molecular targets and can effectively inhibit the growth and proliferation of leukemia and lymphoma cells, thereby improving patients' symptoms and quality of life. When using acotinib to treat the above diseases, an individualized treatment plan should be formulated based on the patient's specific situation and the recommendations of clinicians to obtain the best therapeutic effect.